TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy non-pregnant adults aged 18-40 years and children aged 1-17 years~Exclusion Criteria:~* Diarrhea during the past week~* Antibiotic and anti-diarrheal medicine use during the past week~* One or more episodes of diarrhea or abdominal pain lasting for 2 weeks during the past 6 months~* Abdominal pain, nausea, vomiting, loss of appetite or generalized ill feeling for the past 24 hours~* Pregnancy

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Killed Whole Cell Oral Cholera Vaccine
- 2 (Type: PLACEBO_COMPARATOR): Heat-killed E. coli

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male~* African American by self-report~* Subjects will be defined as having diabetes if they are diagnosed with diabetes per the American Diabetes Association guidelines~* Subjects without diabetes or impaired glucose tolerance will have a fasting blood glucose \<100 mg/dL and/or glycosylated hemoglobin(A1C) \<6.5%.~Exclusion Criteria:~* Females~* Self report of race or ethnicity other than African~* Currently taking any lipid-lowering medications

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- T2DM (Type: None): African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
- Control (Type: None): African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant has a diagnosis of essential hypertension.~* Participant is not treated with antihypertensive medication and meets protocol-specified blood pressure criteria.~* Participant is treated with single antihypertensive medication, and meets protocol-specified blood pressure criteria.~* Participant is being treated with up to dual oral antihypertensive medications, and will be able to discontinue the prior antihypertensive medication.~* Participant has no clinically meaningful findings to be disqualified from the study at the discretion of the investigator.~Exclusion criteria:~* Regarding hypertension, participant is currently taking \> 2 antihypertensive medications.~* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing chlortalidone medicines)~* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or a recent history within the last year of drug or alcohol abuse or dependence.~* Participant is pregnant or breastfeeding or expecting to conceive or has a positive pregnancy test at the screening visit.~* Participant is currently participating or has participated in a study with an investigational compound (except losartan at any doses) or device within 30 days of signing informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MK-0954A (Type: EXPERIMENTAL): Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
- Losartan (Type: ACTIVE_COMPARATOR): Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: H-IVIG Treatment for Severe H1N1 2009

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (fulfill all criteria): male or female patients 18 years or older~* written informed consent by patient or next of kin (if patients too ill)~* diagnosis of H1N1 2009 infection satisfying both clinical and laboratory criteria:~  1. Laboratory criteria: at least one RT-PCR positive for H1N1 2009 from one of the clinical specimens (NPA, ETA, blood, urine or stool).~ 2. Clinical criteria: patients admitted to ICU with severe community acquired pneumonia as defined by a CURB-65 score of 3 or more~* deterioration during treatment with optimal antiviral (oral or inhaler agents only) and typical and atypical antimicrobial coverage~* required ICU and ventilatory support and within 7 days onset of symptoms.~Exclusion Criteria:~* age below 18 years~* known hypersensitivity to immune globulin or any components of the formulation~* known IgA deficiency~* acquire the H1N1 2009 infection from health care facility~* moribund patients or refusal of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous immunoglobulin (Type: ACTIVE_COMPARATOR): Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
- Hyperimmune intravenous immunoglobulin (Type: EXPERIMENTAL): Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in at least one eye.~* Females of childbearing potential must utilized reliable contraceptive methods and have a negative pregnancy test.~Exclusion Criteria:~* Pregnant or nursing females.~* Known hypersensitivity to fluoroquinolones or to any of the study ingredients.~* Use of any antibiotic within 72 hours of treatment.~* Any disease or condition that could interfere with the safety and efficacy evaluations of the study medications.~* Participation in an ophthalmic drug or device research study within 30 days prior to entry into the study.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-403 (Type: EXPERIMENTAL): 0.6% ISV-403 ophthalmic suspension
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle of ISV-403 ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria~2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia~3. Subjects experiencing an acute exacerbation of psychotic symptoms~4. Other protocol specific inclusion criteria may apply~Exclusion Criteria:~1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~2. Subjects with a current DSM-IV-TR Axis I diagnosis of:~   * Schizoaffective disorder~  * MDD~  * Bipolar disorder~  * Delirium, dementia, amnestic or other cognitive disorder~  * Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder~3. Subjects presenting with a first episode of schizophrenia~4. Other protocol specific exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dose 3 OPC 34712 (Type: EXPERIMENTAL): Higher dose, tablet, once daily, for six weeks
- Dose 2 OPC 34712 (Type: EXPERIMENTAL): Middle dose, tablet, once daily, for six weeks
- Dose 1 OPC 34712 (Type: EXPERIMENTAL): Lower dose, tablet, once daily, for six weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, once daily, for six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chewing Gum on Gastrointestinal Function Recovery After Surgery of Gynecological Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Female patients preparing for complete surgical staging for malig- nant gynecologic disease such as endometrial cancer, cervix cancer and ovarian cancer were assessed for eligibility.~* age 18-60 yr~* good consciousness~Exclusion Criteria:~* Exclusion criteria for the study included thyroid diseases, inflammatory bowel disease, complaints of chronic constipation (defined as two or fewer bowel movements per week), a history of prior abdominal bowel surgery, abdominal radiation, or neoadjuvant chemotherapy, need for intensive care more that 24 h postoperatively, nasogastric tube drainage beyond the first postopera- tive morning, or bowel anastomosis and upper abdominal multivisceral surgical approaches in relation to the debulking surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gum chewing (Type: EXPERIMENTAL): Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function.
- Control group (Type: NO_INTERVENTION): no gum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subacromial impingement syndrome~* MRI with intact rotator cuff~* Patients suitable for general anaesthesia~Exclusion Criteria:~* Known major joint trauma, infection, avascular necrosis, chronic dislocation, inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen shoulder or previous surgery of the affected shoulder~* Abnormal ECG~* Prolonged QT syndrome~* Current or regular use of analgesic medication for other indication(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SABER-Bupivacaine Treatment 1a (Type: EXPERIMENTAL): double-blind
- Placebo SABER-Bupivacaine Treatment 1b (Type: PLACEBO_COMPARATOR): double-blind
- Bupivacaine HCl Treatment 1c (Type: ACTIVE_COMPARATOR): double-blind
- SABER-Bupivacaine Treatment 2a (Type: EXPERIMENTAL): double-blind
- Placebo SABER-Bupivacaine Treatment 2b (Type: PLACEBO_COMPARATOR): double-blind
- Bupivacaine HCl Treatment 2c (Type: ACTIVE_COMPARATOR): double-blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with documented diagnosis of primary osteoarthritis (OA) of the target knee made at least 3 months prior to Screening,~* Has radiographic evidence of OA in the tibio-femoral compartment of the target, knee with at least 1 definite osteophyte and a measureable joint space, as diagnosed by standard X-rays taken not longer than 3 months prior to Screening, and before any baseline assessment,~* Has continued target knee pain despite conservative treatment (e.g. weight reduction, physical therapy, analgesics),~* Has pain in the target knee as demonstrated by a score of 2 or 3 on the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A1 (Walking Pain) Subscale ,~* Has a mean score of 1.5 to 3.5 on the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A (Pain) Subscale.~* Inclusion Criteria for Repeat Phase: Must have no major safety concerns during the first course of treatment as assessed by the Investigator; Must have a WOMAC LK 3.1 A score of at least 1.~Exclusion criteria:~* Has modified Kellgren-Lawrence Numerical Grading System of grade IV in the patello-femoral compartment of the target knee confirmed by standard X-rays taken not longer than 3 months prior to Screening, and before any baseline assessment,~* Has clinically apparent tense effusion of the target knee,~* Has had viscosupplementation in any joint including the target knee within 9 months prior to Screening,~* Has concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc.,)~* Symptomatic OA of the contralateral knee or of either hip that is not responsive to paracetamol and requires other therapy,~* Has related hypersensitivities to avian proteins and/or any components of hyaluronan-based injection devices,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Synvisc (Type: EXPERIMENTAL): Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
- Saline Control (Type: PLACEBO_COMPARATOR): Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgically confirmed endometriosis~* Age between 15-40 y, and premenopausal~* Pelvic pain score ≥3 on a Visual Analog Scaleover the last month~Exclusion Criteria:~* Use of other concurrent hormone medications (such as birth control pills)~* Impaired liver function (ALT \> 2x normal) or liver disease (cirrhosis, hepatitis)~* Pregnancy~* Breast cancer~* Active thromboembolic disease~* Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Norethindrone acetate 5 mg po daily x 6 months
- Experimental (Type: EXPERIMENTAL): cabergoline 0.5 mg PO twice weekly x 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who receive explanation on this study and give informed consent~* Patients aged 30 to 85 years~* Baseline NIHSS less than 15~* Onset of symptoms within 48 hours of the start of investigational product~* Full functional independence prior to the present stroke indicated by an mRS score of 0, 1, 2~Exclusion Criteria:~* Evidence from CT or MRI scan of an acute intracranial hemorrhage, a tumor, encephalitis or any diagnosis other than acute ischemic stroke likely to cause the present symptoms.~* Previous regular use of an antiplatelet agent or warfarin~* Patients with known cardiac disease likely to cause cardiogenic embolism or congestive heart failure~* Evidence from CT or MRI scan of midline shift when visiting hospital~* Uncontrolled hypertension (SBP\>220 mmHg or DBP\>120 mmHg)~* Hypotension (\<90/60 mmHg)~* Patients with known bleeding diathesis or coagulation disorder~* Patients with liver disease (ALT\>100 or AST\>100), or renal disease (creatinine\>2.0 mg/dl)~* Known severe anaemia (hemoglobin\<8.0 mg/dl), or thrombocytopenia (platelet\<100,000/mm3)~* Scheduled for endarterectomy within 3 months~* Severe co-morbidity likely to limit patient's life expectancy to less than 6 months~* Patients with alcohol or illegal drug abuse or dependency~* Pregnant or lactating patients. When administrating to females, it should be confirmed that the patients is in the menopause (by evaluation of investigators) or permanently infertile (hysterectomy or surgical operation like bilateral tubal ligation, bilateral oophorectomy, etc). If a patient is likely to be pregnant, the patient should not be pregnant before randomization. And, the patient should use reliable contraception between at least 3 weeks before randomization to 7 days after the final administration of study drug.~* Patients treated by thrombolytic agents like tPA after onset of stroke

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic non small cell lung cancer~* Undertaken EGFR TKIs treatment (gefitinib, erlotinib, icotinib, afatinib, etc)~  * 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance score 0-2~* Moderate or severe pruritus (VAS score ≥ 4) first occur after EGFR TKIs treatment~* Life expectancy ≥ 3 months~* Orally drug administration with no difficulty~* pregnancy test negative in 7 days for women of child-bearing age; willing to take contraception measures.~* Signed informed consent form (ICF)~Exclusion Criteria:~* Systemically treatment with Neurokinin-1 (NK-1) receptor inhibitors, antihistamines drugs, antibiotics, cortical hormone therapy, antiepileptic drugs, immunosuppressive agents or other drugs might affect treatment in 4 weeks; or locally used of these drug in 2 weeks.~* Existing skin lesions not EGFR TKIs related, such as skin infection, chronic dermatitis, Systemic Lupus Erythematosus (SLE), lymphoma or other diseases.~* Total bilirubin ≥ 1.5 Upper Limit Of Normal (ULN)~* Serum creatinine ≥mg/dl~* AST or ALT ≥ 2.5 ULN without liver metastasis; or ≥ 5 ULN with liver metastasis.~* Residual toxicity event ≥ CTC-AE grade 2, except peripheral neurotoxicities.~* Central nervous system (CNS) metastasis or spinal compression; except no symptoms and with no cortical hormonotherapy in 4 weeks.~* Clinical evidence of interstitial lung disease~* Any severe or uncontrolled systemic diseases judged by investigators.~* Any contraindication of Neurokinin-1 receptor inhibitors and desloratadine.~Discontinuation Criteria~* Invalid subject after randomization~* Major protocol violations judged by investigators.~* Poor compliance~* Intolerable adverse events~* Subject withdraw ICF~* Any pregnancy events~* No clinical benefits due to clinical adverse events, laboratory abnormalities or other medical conditions~* Other reasons of treatment discontinuation judged by investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant and placebo (Type: EXPERIMENTAL): aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
- desloratadine and placebo (Type: ACTIVE_COMPARATOR): placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete